drugset / Trial / NCT00005044

Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer

NCT00005044 ↗

RandomizedParallel-groupOpen-labelTreatment

Summary

RATIONALE: Hormones can stimulate the growth of prostate cancer cells. Hormone therapy may fight prostate cancer by reducing the production of androgens. Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known which regimen of hormone therapy and radiation therapy is more effective for prostate cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of two different regimens of hormone therapy and radiation therapy in treating patients who have prostate cancer.

Timeline

Start
2000-02
Primary completion
2012-09
Completion
2022-05-20

Outcome

Missed primary endpoint

registry analysis (superiority test); TAS x 8 Weeks vs TAS x 28 Weeks; p = 0.45; Hazard Ratio (HR) 0.81 (95% CI 0.48 to 1.39); Log Rank NCT00005044 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Bicalutamide Other / unclassified 50 mg Oral
Subject Flutamide Small molecule 250 mg Oral
Subject Goserelin Other / unclassified — Other
Subject Leuprolide Other / unclassified — Other

Indications